Laboratory of Immunopathology Keizo Asami (LIKA), Federal University of Pernambuco (UFPE), Av. Prof. Moraes Rego, 1235, Cidade Universitária, Recife, PE, 50670-901, Brazil.
Nova Esperança University Hospital (HUNE), João Pessoa, PB, Brazil.
Braz J Microbiol. 2021 Mar;52(1):267-278. doi: 10.1007/s42770-020-00406-x. Epub 2020 Nov 24.
Due to the severity of infections caused by P. aeruginosa and the limitations in treatment, it is necessary to find new therapeutic alternatives. Thus, the use of silver nanoparticles (AgNPs) is a viable alternative because of their potential actions in the combat of microorganisms, showing efficacy against Gram-positive and Gram-negative bacteria, including multidrug-resistant microorganisms (MDR). In this sense, the aim of this work was to conduct a literature review related to the antibacterial and antibiofilm activity of AgNPs against antibiotic-sensitive and multidrug-resistant Pseudomonas aeruginosa strains. The AgNPs are promising for future applications, which may match the clinical need for effective antibiotic therapy. The size of AgNPs is a crucial element to determine the therapeutic activity of nanoparticles, since smaller particles present a larger surface area of contact with the microorganism, affecting their vital functioning. AgNPs adhere to the cytoplasmic membrane and cell wall of microorganisms, causing disruption, penetrating the cell, interacting with cellular structures and biomolecules, and inducing the generation of reactive oxygen species and free radicals. Studies describe the antimicrobial activity of AgNPs at minimum inhibitory concentration (MIC) between 1 and 200 μg/mL against susceptible and MDR P. aeruginosa strains. These studies have also shown antibiofilm activity through disruption of biofilm structure, and oxidative stress, inhibiting biofilm growth at concentrations between 1 and 600 μg/mL of AgNPs. This study evidences the advance of AgNPs as an antibacterial and antibiofilm agent against Pseudomonas aeruginosa strains, demonstrating to be an extremely promising approach to the development of new antimicrobial systems.
由于铜绿假单胞菌感染的严重性和治疗的局限性,有必要寻找新的治疗方法。因此,使用银纳米粒子(AgNPs)是一种可行的选择,因为它们在对抗微生物方面具有潜在的作用,对革兰氏阳性和革兰氏阴性细菌(包括多药耐药菌)具有疗效。从这个意义上说,本工作的目的是对银纳米粒子对抗抗生素敏感和多药耐药铜绿假单胞菌菌株的抗菌和抗生物膜活性进行文献综述。AgNPs 具有广阔的应用前景,可能符合有效抗生素治疗的临床需求。AgNPs 的尺寸是决定纳米粒子治疗活性的关键因素,因为较小的颗粒与微生物的接触表面积更大,从而影响其重要的功能。AgNPs 黏附在微生物的细胞质膜和细胞壁上,导致其破裂,穿透细胞,与细胞结构和生物分子相互作用,并诱导活性氧和自由基的产生。研究表明,AgNPs 的抗菌活性在最小抑菌浓度(MIC)为 1 至 200μg/mL 之间,对敏感和多药耐药的铜绿假单胞菌菌株有效。这些研究还通过破坏生物膜结构和氧化应激来显示抗生物膜活性,AgNPs 的浓度在 1 至 600μg/mL 之间可抑制生物膜生长。本研究证明了 AgNPs 作为一种针对铜绿假单胞菌菌株的抗菌和抗生物膜剂的进步,为开发新的抗菌系统提供了极具潜力的方法。